Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

Calcium channel blockers may raise prostate cancer risk

11 Sep 2020

Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.

Researchers searched multiple online databases for relevant studies and applied fixed effects models to examine the association between CCB use and the risk of prostate cancer. They also assessed the quality using the Newcastle–Ottawa Scale and quantified between-study heterogeneity.

A total of 19 studies involving 1,418,407 patients were included the meta-analysis. These studies were a mix of cohort studies, nested case–control studies, and case–control studies. Pooled data showed that CCB use conferred about a 7-percent increase in the overall risk of prostate cancer (risk ratio [RR], 1.08, 95 percent confidence interval [CI], 1.05–1.11; p<0.00001; hazard ratio, 1.07, 95 percent CI, 1.02–1.13; p=0.008).

Moreover, the results of subgroup analysis revealed that the longer the exposure to CCB, the greater the risk of developing prostate cancer. The risk increased by 8 percent among CCB users of <5 years (RR, 1.08, 95 percent CI, 1.04–1.12; p=0.0001) and by 13 percent among users of 5–10 years (RR, 1.13; 95 percent CI, 1.04–1.23; p=0.003).

Conversely, the risk increase associated with CCB use might be attenuated in the presence of TMPRSS2:ERG or T2E (fusion gene).
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.